Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis

医学 重症监护医学 急诊医学 大流行 梅德林 疾病 接种疫苗 人口 流行病学 儿科 死亡率 入射(几何)
作者
Wenshuo Zhao,Rongna Lian,Yunli Zhao,Zhenran Li,Ming Liu,Fengwen Yang,Junhua Zhang,Jinhui Tian,Fuzhong Xue,Ya Gao
出处
期刊:The Lancet Healthy Longevity [Elsevier BV]
卷期号:7 (6): 100870-100870 被引量:1
标识
DOI:10.1016/j.lanhl.2026.100870
摘要

Background The comparative efficacy and safety of high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in adults 65 years or older remain uncertain. Hence, we aimed to compare the effects of HD-IIV versus those of SD-IIV for hospitalisation and mortality outcomes in this population by synthesising evidence from randomised controlled trials (RCTs). Methods In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Global Health, and ClinicalTrials.gov from inception to Sept 3, 2025, for randomised trials comparing HD-IIV (60 μg of haemagglutinin per strain) with SD-IIV (15 μg of haemagglutinin per strain) in adults aged 65 years or older. We excluded trials of adjuvanted or recombinant vaccines and those conducted during the 2009–10 H1N1 pandemic because the antigenic profile differed from seasonal strains. Pairs of reviewers independently screened studies and extracted aggregate data from eligible reports. Prespecified primary outcomes were hospitalisation for influenza or pneumonia, hospitalisation for influenza, hospitalisation for pneumonia, hospitalisation for laboratory-confirmed influenza, hospitalisation for cardiorespiratory disease, all-cause hospitalisation, and all-cause mortality; serious adverse events (SAEs) were the secondary outcome. We did random-effects meta-analyses and used risk ratio (RR) estimates and baseline risks to calculate absolute risk differences (ie, the difference in absolute number of events per 10 000 vaccinated individuals between SD-IIV and HD-IIV groups) for each outcome. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and the certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation framework. The protocol was registered with the OSF Registry. Findings A total of 1422 records were identified. After screening 813 titles and abstracts, from which 84 full texts were assessed for eligibility, 14 unique RCTs with 581 845 participants were eligible and included in the analyses. Of the 49 outcome results assessed, 32 were rated as low risk of bias and 17 as having some concerns. Compared with SD-IIV, HD-IIV reduced hospitalisation for influenza (RR 0·61 [95% CI 0·50–0·74]; I 2 =0%; absolute risk difference −4 events per 10 000 vaccinated individuals [95% CI −5 to −3]; high certainty), hospitalisation for laboratory-confirmed influenza (RR 0·68 [0·58–0·80]; I 2 =0%; absolute risk difference −4 events per 10 000 vaccinated individuals [−5 to −3]; high certainty), hospitalisation for cardiorespiratory disease (RR 0·92 [0·86–0·98]; I 2 =5·9%; absolute risk difference −15 events per 10 000 vaccinated individuals [−26 to −4]; high certainty), and all-cause hospitalisation (RR 0·97 [0·95–0·99]; I 2 =8·7%; absolute risk difference −29 events per 10 000 vaccinated individuals [−48 to −10]; high certainty). There was probably little or no difference between the effects of HD-IIV and SD-IIV on all-cause mortality (RR 0·98 [0·92–1·05]; I 2 =0·0%; absolute risk difference −1 event per 10 000 vaccinated individuals [−4 to 3]; moderate certainty). Compared with SD-IIV, HD-IIV might have little or no effect on hospitalisation for influenza or pneumonia (RR 0·83 [0·66–1·03]; I 2 =71·3%; absolute risk difference −7 events per 10 000 vaccinated individuals [−14 to 1]; low certainty), hospitalisation for pneumonia (RR 0·85 [0·66–1·08]; I 2 =72·0%; absolute risk difference −9 events per 10 000 vaccinated individuals [−21 to 5]; low certainty), or SAEs (RR 0·97 [0·93–1·01]; I 2 =16·4%; absolute risk difference −18 events per 10 000 vaccinated individuals [−41 to 6]; low certainty). Interpretation HD-IIV could be considered as a strategy to reduce hospitalisation burden in adults 65 years or older; however, the evidence does not support routine preferential use across all older adults irrespective of context. Absolute benefits were modest on average, and the value of HD-IIV is likely to depend on baseline risk, health-care context, and implementation considerations. Funding National Natural Science Foundation of China Youth Science Fund and Shandong Provincial Natural Science Foundation Youth Science Fund.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
顾矜的应助被笔落惊风雨采纳,获得10
1秒前
1秒前
1秒前
1秒前
ZMH完成签到 ,获得积分10
1秒前
1秒前
Shengee发布了新的文献求助10
2秒前
今后的应助被阳阳阳采纳,获得10
2秒前
牧野小曾完成签到,获得积分10
2秒前
Toro完成签到,获得积分10
3秒前
迷你的衬衫完成签到 ,获得积分10
3秒前
CipherSage的应助被查都到采纳,获得10
4秒前
科研通AI2S的应助被bean采纳,获得10
4秒前
摩登C位发布了新的文献求助10
5秒前
科研通AI65的应助被Alice采纳,获得10
5秒前
5秒前
丘比特的应助被有机分子笼采纳,获得10
5秒前
外向的问儿完成签到 ,获得积分10
5秒前
茧茧完成签到,获得积分10
6秒前
7秒前
科研通AI6.3的应助被7788采纳,获得10
7秒前
马嘎嘎发布了新的文献求助10
7秒前
7秒前
郭雪雪发布了新的文献求助10
7秒前
关添发布了新的文献求助10
8秒前
8秒前
medsci发布了新的文献求助10
8秒前
Shengee完成签到,获得积分10
8秒前
9秒前
9秒前
Hello的应助被姜锦令采纳,获得10
10秒前
10秒前
11秒前
11秒前
12秒前
12秒前
程xx完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451